AVXL beat EPS expectations by 14.22%
Aug 06, 2024, 12:33 PM
0.00%
What does AVXL do
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company based in New York, develops therapeutics for neurodegenerative and neurodevelopmental disorders, utilizing precision medicine and genomic data to identify biomarkers. Its lead compound, ANAVEX 2-73, targets Alzheimer’s, Parkinson’s, and other CNS diseases, including Rett syndrome.
Anavex Life Sciences (AVXL) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Anavex Life Sciences's actual EPS was -$0.14, beating the estimate of -$0.16 per share, resulting in a 14.22% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.